Clinuvel Pharmaceuticals Limited (CLVLF)
USD 8.45
(0.0%)
USD 8.45
(0.0%)
| Breakdown | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | 37.05 Million | 36.91 Million | 39.87 Million | 19.26 Million | 14.18 Million | 18.45 Million |
| Net Income | 35.63 Million | 30.6 Million | 20.87 Million | 24.72 Million | 15.05 Million | 18.13 Million |
| Depreciation & Amortization | 1.14 Million | 789.4 Thousand | 757.82 Thousand | 861.43 Thousand | 446.12 Thousand | 214.16 Thousand |
| Deferred income taxes | - | -8.98 Million | 6.06 Million | 880.31 Thousand | -3.51 Million | -19.33 Thousand |
| Stock-based compensation | - | 8.98 Million | 6.12 Million | 2.6 Million | 1.65 Million | 139.93 Thousand |
| Change in working capital | -6.44 Million | -3.21 Million | 5.89 Million | -11.41 Million | 1.81 Million | 809.64 Thousand |
| Other non-cash items | 14.78 Million | 8.73 Million | 8.11 Million | 17.32 Million | 222.51 Thousand | -1.2 Million |
| Investing Cash Flow | -29.03 Million | -1.02 Million | -434.43 Thousand | -854.32 Thousand | -888.82 Thousand | -257.61 Thousand |
| Investments in PPE | -5.57 Million | -1.02 Million | -434.43 Thousand | -854.32 Thousand | -888.82 Thousand | -257.61 Thousand |
| Acquisitions | - | - | - | - | - | - |
| Investment purchases | -23.45 Million | - | - | - | - | - |
| Sales/Maturities of investments | - | - | - | - | - | - |
| Other Investing Activities | - | - | - | - | - | - |
| Financing Cash Flow | -3.57 Million | -2.24 Million | -1.5 Million | -1.47 Million | -1.48 Million | -1.03 Million |
| Debt repayment | - | -263.71 Thousand | -268.49 Thousand | -200.28 Thousand | -18.5 Thousand | -73.5 Thousand |
| Dividends payments | -2.47 Million | -1.97 Million | -1.23 Million | -1.23 Million | -1.22 Million | -957.16 Thousand |
| Common Stock Repurchased | -4.9 Million | - | - | - | - | - |
| Common Stock Issuance | 4.15 Million | - | - | - | - | - |
| Other Financing Activities | -347.34 Thousand | -263.71 Thousand | -268.49 Thousand | -244.68 Thousand | -243.34 Thousand | -3879.00 |
| Accounts receivables | -4.02 Million | -6.01 Million | -113.41 Thousand | -9.47 Million | -2.45 Million | 934.05 Thousand |
| Accounts payables | -648.31 Thousand | 4.51 Million | -1.56 Million | -20.44 Thousand | 2.66 Million | 1.51 Million |
| Inventory | -1.1 Million | -7.68 Million | 1.35 Million | -1.89 Million | 848.17 Thousand | -1.49 Million |
| Other working capital | -664.94 Thousand | 5.96 Million | 6.21 Million | -22.15 Thousand | 765.14 Thousand | -141.44 Thousand |
| Cash at beginning of period | 31.89 Million | 121.5 Million | 82.69 Million | 66.74 Million | 54.26 Million | 36.19 Million |
| Cash at end of period | 35.2 Million | 156.81 Million | 121.5 Million | 82.69 Million | 66.74 Million | 54.26 Million |
| Capital Expenditure | -5.57 Million | -1.02 Million | -434.43 Thousand | -854.32 Thousand | -888.82 Thousand | -257.61 Thousand |
| Effect of forex changes on cash | -1.14 Million | 1.65 Million | 884.21 Thousand | -983.32 Thousand | 664.08 Thousand | 902.48 Thousand |
| Net cash flow / Change in cash | 3.3 Million | 35.3 Million | 38.81 Million | 15.94 Million | 12.47 Million | 18.07 Million |
| Free Cash Flow | 31.47 Million | 35.88 Million | 39.43 Million | 18.4 Million | 13.29 Million | 18.19 Million |
| Breakdown | 2024 FY | 2024 Q4 | 2024 Q2 | 2024 Q1 | 2023 Q4 | 2023 FY |
|---|---|---|---|---|---|---|
| Operating Cash Flow | - | - | - | - | - | - |
| Net Income | 35.63 Million | 24.7 Million | 10.93 Million | 5.46 Million | 19.21 Million | 30.6 Million |
| Depreciation & Amortization | 1.14 Million | 566.89 Thousand | 575.43 Thousand | 287.71 Thousand | 413.32 Thousand | 789.4 Thousand |
| Deferred income taxes | - | - | - | - | 4.14 Million | -8.98 Million |
| Stock-based compensation | - | - | 2.82 Million | 2.82 Million | 2.58 Million | 8.98 Million |
| Change in working capital | -6.44 Million | - | - | - | -7.55 Million | -3.21 Million |
| Other non-cash items | 14.78 Million | -13.45 Million | 16.01 Million | 4.61 Million | -2.91 Million | 8.73 Million |
| Investing Cash Flow | -29.03 Million | -13.02 Million | -16.01 Million | -8 Million | -632.44 Thousand | -1.02 Million |
| Investments in PPE | -5.57 Million | -274.66 Thousand | -5.3 Million | -2.65 Million | -632.44 Thousand | -1.02 Million |
| Acquisitions | - | - | - | - | - | - |
| Investment purchases | -23.45 Million | -12.74 Million | -10.71 Million | - | - | - |
| Sales/Maturities of investments | - | - | - | - | - | - |
| Other Investing Activities | - | - | -5.35 Million | -5.35 Million | - | - |
| Financing Cash Flow | -3.57 Million | -937.31 Thousand | -2.63 Million | -1.31 Million | -94.06 Thousand | -2.24 Million |
| Debt repayment | - | - | - | - | - | -263.71 Thousand |
| Dividends payments | -2.47 Million | - | -2.47 Million | -1.23 Million | - | -1.97 Million |
| Common Stock Repurchased | -4.9 Million | -4.9 Million | - | - | - | - |
| Common Stock Issuance | 4.15 Million | 4.15 Million | - | - | - | - |
| Other Financing Activities | -347.34 Thousand | - | -82.13 Thousand | -82.13 Thousand | -47.03 Thousand | -263.71 Thousand |
| Accounts receivables | -4.02 Million | - | - | - | -3 Million | -6.01 Million |
| Accounts payables | -648.31 Thousand | - | - | - | - | 4.51 Million |
| Inventory | -1.1 Million | - | - | - | -3.84 Million | -7.68 Million |
| Other working capital | -664.94 Thousand | - | - | - | -705.39 Thousand | 5.96 Million |
| Cash at beginning of period | 31.89 Million | 38.81 Million | 23.86 Million | - | 140.7 Million | 121.5 Million |
| Cash at end of period | 35.2 Million | 35.2 Million | 38.81 Million | 3.46 Million | 23.86 Million | 156.81 Million |
| Capital Expenditure | -5.57 Million | -274.66 Thousand | -5.3 Million | -2.65 Million | -632.44 Thousand | -1.02 Million |
| Effect of forex changes on cash | -1.14 Million | - | -404.07 Thousand | -404.07 Thousand | 473.82 Thousand | 1.65 Million |
| Net cash flow / Change in cash | 3.3 Million | -3.61 Million | 14.94 Million | 3.46 Million | -116.83 Million | 35.3 Million |
| Free Cash Flow | 31.47 Million | 10.39 Million | 21.07 Million | 10.53 Million | 15.25 Million | 35.88 Million |
RNUGF
CVX
JPDYY
8848
USFD
6902